Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: NASDAQ CM
  • Sector: Health Care
  • Industry: Medical Equipment & Devices
  • Sub-Industry: Life Science Equipment

Exact Sciences Corp

+ Add to Watchlist

EXAS:US

27.7200 USD 0.5100 1.81%

As of 13:25:16 ET on 01/28/2015.

Snapshot for Exact Sciences Corp (EXAS)

Open: 28.4400 Day's Range: 27.5000 - 28.6300 Volume: 368,301
Previous Close: 28.2300 52wk Range: 10.6900 - 29.9700 1-Yr Rtn: +108.65%

Stock Chart for EXAS

No chart data available.
  • EXAS:US 27.7200
  • 1D
  • 1M
  • 1Y
28.2300
Interactive EXAS Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for EXAS

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -1.0300
Est. EPS (USD) (12/2014) -1.2550
Est. PEG Ratio -
Market Cap (M USD) 2,471.47
Shares Outstanding (M) 88.58
30 Day Average Volume 1,609,013
Price/Book (mrq) 10.6630
Price/Sale (ttm) 1,468.3284
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 02/20/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for EXAS

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for EXAS

Exact Sciences Corp., is focused on developing and commercializing a non-invasive molecular screening test for the early detection and prevention of colorectal cancer. The Company's test is a stool-based DNA test that identifies both pre-cancer and cancer by detecting genetic mutations in colorectal cancer cells.

Kevin T ConroyChairman/President/CEOManeesh K AroraChief Operating Officer
Graham P LidgardSenior VP/Chief Science OfcrScott CowardSenior VP/General Counsel
More Company Profile & Key Executives for EXAS

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil